Pharmacotherapeutic options in the treatment of amyotrophic lateral sclerosis

Formulary

Volumn 33, Issue 1, 1998, Pages 44-53

  White, Laura R ^a   Felice, Kevin J ^b   Chow, Moses S S ^c,d  

^a Health Management Programs   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d Hartford (CT) Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344992701     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Festoff BW. Amyotrophic lateral sclerosis: Current and future treatment strategies. Drugs 1996;51:28-44.
2. Nelson LM. Epidemiology of ALS. Clin Neurosci 1996;3:327-31.
3. The ALS Association. Family Caregiver Alliance fact sheet: Amyotrophic lateral sclerosis. Family Caregiver Alliance 1996.
4. ALS Brochure. American Academy of Neurology.
5. Brooks BR. Clinical epidemiology of amyotrophic lateral sclerosis. Neurol Clin 1996;14:399-420.
6. Mitsumoto H. Diagnosis and progression of ALS. Neurology 1997;48(Suppl 4):S2-8.
7. Siddique T, Hentati A. Familial amyotrophic lateral sclerosis. Clin Neurosci 1996;3:338-47.
8. Cudkowicz ME, Brown RH. An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis. J Neurol Sci 1996;139(Suppl):10-15.
9. Rowland LP. Amyotrophic lateral sclerosis. Curr Opin Neurol 1994;7:310-15.
10. Jerusalem F, Pohl CH, Karitzky J, Ries F. ALS. Neurology 1996;47(Suppl 4):S218-20.
11. Leigh PN, Meldrum BS. Excitotoxicity in ALS. Neurology 1996;47(Suppl 4):S221-7.
12. Plaitakis A. Glutamate dysfunction and selective motor neuron degeneration in amyotrophic lateral sclerosis: A hypothesis. Ann Neurol 1990;28:3-8.
13. Rothstein J. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin Neurosci 1996;3:348-59.
14. Wokke J. Riluzole. Lancet 1996;348:795-9.
15. Brooks BR. Clinical evaluation of ALS drugs. Neurology 1997;48(Suppl 4):S23-7.
16. Leigh PN, Ray-Chaudhuri K. Motor neuron disease. J Neurol Neurosurg Psychiatry 1994;57:886-96.
17. Sufit R. Symptomatic treatment of ALS. Neurology 1997;48(Suppl 4):S15-22.
18. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-91.
19. Miller RG, Sufit R, Mitsumoto H, et al. ALS standard of care consensus. Neurology 1997;48(Suppl 4):S33-7.
20. Gelinas DF. Patient and caregiver communications and decisions. Neurology 1997;48(Suppl 4):S9-14.
21. Riluzole for amyotrophic lateral sclerosis. Med Lett Drugs Ther 1995;37:113-4.
22. Miller RG, Sufit R. New approaches to the treatment of ALS. Neurology 1997;48 (Suppl 4):S28-32.
23. Rilutek package insert. Rhone-Poulenc Rorer Pharmaceuticals Inc, 1996.
24. Lacomblez L, Bensimon G, Leigh PN, et al, for the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amytrophic lateral sclerosis. Lancet 1996;347:1425-31.
25. Elliot JL, Snider WD. Motor neuron growth factors. Neurology 1996; 47(Suppl 2):S47-53.
26. Lewis ME, Neff NT, Contreras PC, et al. Insulin-like growth factor-I: Potential for treatment of motor neuronal disorders. Exp Neurol 1993;124:73-88.
27. Lai EC, Felice KJ, Festoff BW, et al, and the North American ALS/IGF-I Study Group. Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study. Neurology 1997;49:1621-30.
28. Borasio GD, De Jong JMBV, Emile J, et al, and the European ALS/IGF-I study group. Insulin-like growth factor I in the treatment of amytrophic lateral sclerosis: Results of the European multicenter, double-blind, placebo-controlled trial (abstract). J Neurol 1996;248(Suppl 2):5.
29. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHC-NTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-9.
30. Miller RG, Petajan JH, Bryan WW, et al, and the rhCNTF ALS Study Group. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-60.
31. Cory PR, Gidal BE. Potential use of gabapentin and lamotrigine. Ann Pharmacother 1995;29:1160-1.
32. Miller RG, Moore D, Young LA, et al, for the WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996;47:1383-88.
33. Eisen A, Stewart H, Schultzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine. Can J Neurol Sci 1993;20:297-301.
34. Hugon J. ALS therapy: Targets for the future. Neurology 1996;47(Suppl 4):S251-4.
35. Louwerse ES, Weverling GJ, Bossuyt PM, et al. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-64.
36. The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology 1993;43:2466-70.
37. The NDA pipeline-1996. 15th ed. Chevy Chase, MD: FDC reports.
38. What's in the pipeline. MedAd News 1997.